PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA Drug Patent Profile

Which patents cover Photrexa Viscous In Dextran 20%/photrexa, and when can generic versions of Photrexa Viscous In Dextran 20%/photrexa launch?

Photrexa Viscous In Dextran 20%/photrexa is a drug marketed by Glaukos and is included in one NDA.

The generic ingredient in PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the riboflavin 5'-phosphate sodium profile page.

Summary for PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA at DailyMed

US Patents and Regulatory Information for PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaukos	PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA	riboflavin 5'-phosphate sodium	SOLUTION/DROPS;OPHTHALMIC	203324-001	Apr 15, 2016		RX	Yes	Yes

PHOTREXA VISCOUS AND PHOTREXA MARKET DYNAMICS, PATENT POSITION, AND FINANCIAL TRAJECTORY

Last updated: August 2, 2026

Photrexa Viscous and Photrexa are riboflavin ophthalmic products used with the KXL System for corneal collagen cross-linking in progressive keratoconus and corneal ectasia following refractive surgery. The products received FDA approval in 2016 and are commercialized by Glaukos following its acquisition of Avedro. Their commercial value is tied to the installed base of KXL systems, procedure volumes, physician adoption, reimbursement, and the absence of a directly substitutable FDA-approved drug product.

Public company filings do not disclose standalone Photrexa revenue. Glaukos reports the products within its corneal health business, which also includes the iLink procedure and related equipment. The portfolio has strategic value because Photrexa is used with the company’s proprietary cross-linking platform, creating a recurring consumables model rather than a one-time device sale.

What are Photrexa Viscous and Photrexa used for?

Photrexa Viscous is a riboflavin 5'-phosphate ophthalmic solution containing dextran 20%. Photrexa is a lower-viscosity riboflavin ophthalmic solution used during the corneal cross-linking procedure.

The FDA-approved regimen is used with the KXL System for:

• Progressive keratoconus.
• Corneal ectasia following refractive surgery.

The products are applied to the cornea before ultraviolet-A illumination. Riboflavin functions as the photosensitizer, while the KXL System delivers the ultraviolet-A energy required for corneal cross-linking.

Product	Active ingredient	Key excipient or formulation attribute	Primary use
Photrexa Viscous	Riboflavin 5'-phosphate ophthalmic solution	Dextran 20%	Corneal cross-linking
Photrexa	Riboflavin 5'-phosphate ophthalmic solution	Lower-viscosity formulation	Corneal cross-linking
KXL System	Ultraviolet-A ophthalmic device	Proprietary device platform	Delivers cross-linking treatment

The approved treatment is generally referred to commercially as the iLink procedure when performed with Glaukos’s KXL System and Photrexa products.

When did Photrexa receive FDA approval?

The FDA approved Photrexa Viscous, Photrexa, and the KXL System on April 15, 2016. The approval covered corneal collagen cross-linking for progressive keratoconus and corneal ectasia following refractive surgery (U.S. Food and Drug Administration, 2016).

The products were among the first FDA-approved drug-device components specifically authorized for corneal cross-linking in the United States. This regulatory status differentiates Photrexa from pharmacy-compounded riboflavin formulations and from cross-linking systems used outside the approved U.S. indication.

FDA regulatory milestones

Date	Event
April 15, 2016	FDA approval of Photrexa, Photrexa Viscous, and KXL System
2016 onward	Commercial launch of the FDA-approved iLink procedure
2019	Avedro completed its initial public offering
February 2020	Glaukos completed acquisition of Avedro
2020 onward	Photrexa and iLink incorporated into Glaukos’s corneal health business

The FDA approval was based on clinical data showing reduced progression of keratoconus and post-refractive-surgery corneal ectasia in the approved treatment populations.

What is the commercial market for Photrexa?

The addressable market is the U.S. corneal cross-linking market, particularly patients with progressive keratoconus and post-refractive-surgery ectasia. The commercial opportunity depends less on drug pricing than on the number of diagnosed patients receiving treatment and the number of ophthalmology practices equipped to perform the procedure.

Key market drivers include:

1. Rising diagnosis of keratoconus through improved corneal imaging.
2. Earlier intervention before severe visual impairment.
3. Increased availability of corneal cross-linking equipment.
4. Greater physician familiarity with disease progression.
5. Insurance coverage for medically necessary cross-linking.
6. Expansion of treatment beyond major academic centers.

Keratoconus is commonly diagnosed in adolescents and young adults. Treatment demand therefore has a long-duration clinical profile, although a patient generally receives a single treatment per affected eye rather than chronic dosing.

The product’s commercial model has three revenue components:

• Photrexa drug sales.
• KXL System placements or capital equipment sales.
• Procedure-related consumables and service revenue.

The drug itself is central to the recurring revenue model. Once a physician adopts the KXL platform, each treated eye can generate demand for Photrexa products.

How does Photrexa generate revenue for Glaukos?

Glaukos does not separately report Photrexa Viscous or Photrexa net sales in its public filings. Revenue is reported by business segment and product category, limiting product-level financial analysis.

The economic structure is nevertheless identifiable:

Revenue driver	Financial effect
New KXL System placements	Expands future procedure capacity
Photrexa utilization	Creates recurring revenue per treated eye
Procedure growth	Increases drug and consumables demand
Reimbursement expansion	Supports physician adoption
International approvals	Broadens the addressable market
Compounded riboflavin use	Creates price and volume pressure

Glaukos’s broader business includes micro-invasive glaucoma surgery, corneal health, and other ophthalmic products. As a result, consolidated revenue growth cannot be attributed to Photrexa without company-provided product-level reporting.

A financially relevant distinction is that Photrexa is a procedure-linked product, not a traditional chronic prescription drug. Revenue can rise through more procedures even when the number of treated patients remains stable, but it is exposed to elective procedure deferrals, capital budget constraints, reimbursement changes, and surgeon adoption.

What patents protect Photrexa?

Photrexa’s protection is likely distributed across several layers rather than resting solely on a single composition-of-matter patent.

The relevant protection categories include:

Formulation patents

Potential formulation protection may cover:

• Riboflavin concentration.
• Dextran-containing viscosity characteristics.
• Ophthalmic solution stability.
• Packaging and single-use presentation.
• The relationship between formulation properties and corneal treatment.

Photrexa Viscous contains dextran 20%, a feature that distinguishes it from lower-viscosity Photrexa. Formulation claims can be commercially useful but are generally more vulnerable to design-around strategies than a new-molecule patent.

Method-of-use patents

Method claims may address:

• Treating progressive keratoconus.
• Treating post-refractive-surgery corneal ectasia.
• Riboflavin administration before ultraviolet-A exposure.
• Treatment parameters involving corneal thickness, irradiation intensity, and exposure time.
• Use of a riboflavin formulation with a specified cross-linking device.

Method-of-use protection is relevant because a generic or compounded riboflavin product may still face infringement risk if it is marketed for the patented treatment method.

Device and system patents

The KXL System may be protected separately through patents covering:

• Ultraviolet-A delivery.
• Irradiation control.
• Calibration.
• Eye alignment and treatment monitoring.
• Integration of the device with the riboflavin treatment protocol.

Device patents do not necessarily prevent substitution with another ultraviolet-A system. They can, however, support a broader drug-device commercial strategy.

What is the Orange Book status of Photrexa?

FDA Orange Book analysis must distinguish drug listings from device protection. Photrexa products are FDA-approved prescription ophthalmic solutions, but the commercial iLink procedure also depends on the KXL System, which is regulated as a medical device.

Publicly available commercial materials do not establish a complete, current Orange Book patent listing for every Photrexa product and jurisdiction. The FDA approval itself does not prove that a particular patent is listed in the Orange Book. Orange Book-listed patents, if any, would be relevant to abbreviated new drug application certification and Paragraph IV litigation.

The regulatory barriers are therefore broader than Orange Book status:

• The drug product must meet FDA requirements for an ophthalmic solution.
• The labeling must support the proposed use.
• The applicant may need to address listed patents through ANDA certifications.
• A competing product may need to demonstrate pharmaceutical equivalence and bioequivalence.
• A competing cross-linking procedure may require separate device clearance or approval.

When does Photrexa lose exclusivity?

Photrexa’s key exclusivity dates cannot be reduced to one universally applicable expiration date without a current patent and regulatory listing review. FDA statutory exclusivity, patent term, pediatric exclusivity, and litigation-related stays can produce different endpoints.

The principal distinction is:

Protection type	Commercial relevance
New drug exclusivity	Restricts certain FDA approvals for a defined period
Patent protection	Can delay or block competing products until expiration
Orphan exclusivity	Relevant only if the approved product received orphan designation for the indication
Pediatric exclusivity	Can add six months to qualifying patents and exclusivities
Device exclusivity	Arises through device patents and regulatory barriers, not Orange Book protection

The product was approved in 2016, so any five-year new chemical entity exclusivity would have expired. However, Photrexa is a formulation of riboflavin rather than a newly discovered active pharmaceutical ingredient, making the applicable statutory exclusivity framework more limited than for a new molecular entity.

The practical protection period depends on the scope and enforceability of formulation, method, and device patents, together with regulatory complexity.

Are there Paragraph IV challenges to Photrexa?

No widely reported, commercially significant Paragraph IV litigation against Photrexa is established in the major public records commonly used for pharmaceutical patent monitoring through 2024.

The absence of a prominent Paragraph IV case does not eliminate generic risk. A competitor could pursue:

• An ANDA with Paragraph IV certifications.
• A 505(b)(2) application.
• A compounded riboflavin product under applicable pharmacy rules.
• A device-enabled cross-linking product outside the exact approved labeling.
• A non-U.S. regulatory pathway followed by U.S. commercialization.

The most plausible generic strategy would target the riboflavin product while avoiding KXL device claims. A competing company would need to address formulation equivalence, ophthalmic sterility, stability, labeling, and the clinical role of the riboflavin solution in the cross-linking procedure.

How strong is the Photrexa patent estate?

The estate is strategically stronger as a combined drug-device-procedure platform than as a standalone riboflavin formulation franchise.

Strengths

• FDA approval for a defined corneal cross-linking indication.
• Integration with a proprietary device platform.
• Physician and practice workflow lock-in.
• Regulatory and manufacturing requirements for sterile ophthalmic products.
• Potential method-of-use and device patent layers.
• Limited direct substitution for the complete approved procedure.

Weaknesses

• Riboflavin is an established active ingredient.
• Formulation claims may be vulnerable to alternative excipients or concentrations.
• Pharmacy-compounded products may create pricing pressure.
• Device alternatives may weaken system-level exclusivity.
• Product-level patent and revenue information is not fully disclosed publicly.
• The product treats a relatively specialized patient population.

The principal moat is procedural and regulatory. A competitor must reproduce a sterile ophthalmic formulation, establish an acceptable treatment protocol, obtain regulatory authorization, and persuade physicians to adopt a competing platform.

Which companies are challenging Photrexa?

No company has emerged as a publicly established U.S. commercial replacement for the complete Photrexa-KXL iLink procedure through 2024.

Competitive pressure comes from several categories:

Competitor category	Competitive mechanism
Compounding pharmacies	Lower-cost riboflavin formulations
Alternative device manufacturers	Competing ultraviolet-A cross-linking systems
International cross-linking suppliers	Products marketed outside the FDA-approved U.S. framework
Refractive and corneal technology companies	New treatment protocols or delivery systems
Future generic sponsors	FDA-approved riboflavin ophthalmic products

The strongest competitive threat is not necessarily an ANDA product. A company with an alternative device and compatible riboflavin product could compete at the procedure level, although it would face regulatory, clinical, and physician-adoption barriers.

What litigation affects Photrexa?

No major, publicly established patent litigation materially disrupting Photrexa commercialization is identified through 2024. Litigation risk remains possible in four areas:

1. Patent disputes over riboflavin formulations.
2. Method-of-use disputes involving cross-linking protocols.
3. Device patent litigation involving ultraviolet-A systems.
4. Regulatory or commercial disputes concerning compounded preparations.

Glaukos’s acquisition of Avedro transferred the commercial platform, product rights, and related intellectual property into a larger ophthalmic company. That transaction reduced standalone-company risk but made Photrexa financially less transparent because the product is reported within Glaukos’s broader portfolio.

What are the generic launch risks for Photrexa?

A generic launch would probably be gradual rather than an immediate full substitution event.

Scenario 1: No meaningful generic entry

Glaukos retains physician preference, procedure integration, and regulatory advantage. Photrexa remains the default U.S. drug component of the iLink procedure.

Scenario 2: Limited compounded-product pressure

Compounded riboflavin captures price-sensitive practices but does not displace the FDA-approved product in higher-volume or risk-sensitive settings. This scenario would pressure price and margins without eliminating Photrexa demand.

Scenario 3: FDA-approved competing riboflavin

A rival product gains approval and competes on price, supply, or formulation. Glaukos could retain share through KXL integration and clinical familiarity, but drug gross margins and consumable revenue would face pressure.

Scenario 4: Competing drug-device platform

A rival offers an integrated cross-linking system. This would pose the greatest long-term threat because it could affect both Photrexa volume and KXL system placements.

How does Photrexa compare with compounded riboflavin?

Attribute	Photrexa	Compounded riboflavin
FDA-approved product	Yes, for specified indications	Product-specific status varies
Manufacturing controls	Commercial pharmaceutical manufacturing	Pharmacy-dependent
Labeling	FDA-approved labeling	May lack equivalent labeling
Device integration	Designed for approved iLink procedure	May be used with various systems
Price	Typically higher	Often lower
Evidence base	Linked to FDA approval studies	Product and protocol dependent
Commercial risk	Reimbursement and competition	Quality, consistency, and regulatory variability

The main economic advantage of compounding is price. The main commercial advantage of Photrexa is regulatory status, standardized supply, and integration with an FDA-approved treatment system.

What is the international market opportunity?

Glaukos has pursued international commercialization of its corneal cross-linking technology, but country-specific drug approvals, reimbursement, and patent rights differ materially.

International expansion is constrained by:

• Separate regulatory review for riboflavin products.
• Country-specific medical device approvals.
• Local reimbursement policies.
• Physician training requirements.
• Patent term differences.
• Local compounding and import rules.
• Availability of competing cross-linking devices.

U.S. commercial performance should not be extrapolated directly to Europe, Asia, or Latin America. The United States has a distinct reimbursement and FDA framework, while international markets may permit more protocol variation and competition from non-U.S.-approved products.

What is the financial trajectory for Photrexa?

Photrexa’s financial trajectory is best characterized as a recurring, procedure-driven growth asset within Glaukos rather than a separately reported blockbuster drug.

The positive case depends on:

• Growth in diagnosed keratoconus.
• Earlier treatment.
• Higher procedure penetration.
• More KXL placements.
• Improved reimbursement.
• International adoption.
• Continued preference for the FDA-approved product.

The downside case includes:

• Slow procedure adoption.
• Reimbursement reductions.
• Compounded riboflavin substitution.
• Alternative cross-linking systems.
• Manufacturing or supply interruptions.
• Patent challenges.
• Reduced product pricing after competitive entry.

Because Glaukos does not disclose Photrexa-specific revenue, product-level valuation requires estimation from corneal health revenue, installed systems, procedure volumes, and consumable utilization. Any precise Photrexa revenue figure not provided by Glaukos should be treated as an external estimate rather than reported company data.

Key Takeaways

• Photrexa Viscous and Photrexa are FDA-approved riboflavin ophthalmic products used with the KXL System for corneal cross-linking.
• Glaukos acquired Avedro in 2020 and now commercializes the products within its corneal health portfolio.
• Photrexa revenue is not separately disclosed in public company filings.
• The commercial model combines recurring drug consumption with KXL system placements.
• Product protection likely includes formulation, method-of-use, device, and regulatory layers.
• Riboflavin’s established status limits the strength of standalone composition-of-matter protection.
• Compounded riboflavin is the most immediate source of price pressure.
• A competing integrated drug-device platform would represent the greatest strategic threat.
• No major Paragraph IV or patent litigation event materially disrupting Photrexa commercialization is publicly established through 2024.
• Financial upside depends primarily on procedure penetration, reimbursement, and system adoption rather than chronic drug utilization.

FAQs

Is Photrexa Viscous a biologic?

No. Photrexa Viscous is a sterile ophthalmic drug containing riboflavin 5'-phosphate in a dextran 20% formulation.

Does Photrexa treat keratoconus permanently?

Photrexa is used during corneal cross-linking to slow or halt progression. It is not a cure for the underlying corneal disorder and does not directly reverse established corneal deformation.

Can Photrexa be used without the KXL System?

The FDA-approved regimen is associated with the KXL System. Use with another ultraviolet-A device may involve a different regulatory and patent analysis.

Is Photrexa a high-revenue pharmaceutical product?

Its standalone revenue is not publicly reported. Its value is better assessed as part of Glaukos’s recurring corneal cross-linking procedure and consumables business.

What would most likely reduce Photrexa sales?

The most significant risks are an FDA-approved competing riboflavin product, widespread compounded-product substitution, reimbursement reductions, or adoption of a competing integrated cross-linking platform.

References

1. Glaukos Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

2. Glaukos Corporation. (2020, February 7). Glaukos completes acquisition of Avedro. Company press release.

3. U.S. Food and Drug Administration. (2016, April 15). FDA approves first corneal cross-linking system to treat progressive keratoconus and corneal ectasia following refractive surgery. FDA.

4. U.S. Food and Drug Administration. (2023). Photexra Viscous and Photrexa prescribing information. FDA-approved product labeling.

5. Avedro, Inc. (2019). Registration statement on Form S-1. U.S. Securities and Exchange Commission.